Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 29
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
BioNTech SE
BNTX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$87.99
0.93
1.07%
Ult. Agg.: Oct 28, 5:25 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 5 giorni da adesso in mar nov 3rd, prima dell'apertura del mercato
Conference call:
Conference call programmata per tra 5 giorni alle 8:00 AM
Clicca per vedere il webcast
BioNTech Financials
BioNTech (BNTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est
BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 billion-$2.209 billion vs $2.500 billion estimate.
Benzinga Newsdesk
PRO
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst consensus estimate of $(2.34) by 10.26 percent. This is a 41.76 percent decrease over losses of $(1.82) per share from the
Benzinga Newsdesk
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
BioNTech shares fall after Q1 revenue miss and wider net loss, despite lower-than-expected loss and long-term cost-saving plans.
Vandana Singh
Earnings Scheduled For May 5, 2026
Benzinga Insights
PRO
BioNTech Affirms FY2026 Sales Guidance of $2.328B-$2.678B vs $2.560B Est
BioNTech (NASDAQ:BNTX) affirms FY2026 sales outlook from $2.328 billion-$2.678 billion to $2.328 billion-$2.678 billion vs $2.560 billion estimate.
Benzinga Newsdesk
PRO
BioNTech Q1 Adj. EPS $(2.28) Beats $(2.52) Estimate, Sales $138.000M Miss $214.620M Estimate
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.28) per share which beat the analyst consensus estimate of $(2.52) by 9.52 percent. This is a 25.27 percent decrease over losses of $(1.82) per share from the same
Benzinga Newsdesk
